Estrogen use and postmenopausal women: a basis for informed decisions. NIH Consensus Development

Area of Science:

• Reproductive Endocrinology
• Gerontology
• Women's Health

Background:

• Postmenopausal hormone therapy is widely used for symptom management and osteoporosis prevention.
• Estrogen therapy has known benefits but also significant risks, particularly endometrial cancer.
• The role of progestins in mitigating risks and the impact on cardiovascular disease and breast cancer remain areas of concern.

Purpose of the Study:

• To provide a consensus on the benefits and risks of estrogen use in postmenopausal women.
• To highlight areas requiring further research in menopause management.
• To emphasize the importance of individualized treatment decisions.

Main Methods:

• Consensus reached by a panel of experts convened by the National Institute on Aging, National Institutes of Health.
• Review of existing evidence on estrogen therapy in postmenopausal women.
• Discussion of potential benefits, risks, and uncertainties.

Main Results:

• Estrogen therapy alleviates vasomotor symptoms and vaginal atrophy and may prevent osteoporosis.
• Estrogen therapy increases the incidence of endometrial cancer.
• The addition of progestins may prevent endometrial cancer, but associated risks are not fully evaluated.
• Current evidence does not conclusively link postmenopausal estrogen use to cardiovascular disease or breast cancer.

Conclusions:

• Postmenopausal estrogen therapy offers benefits for specific symptoms and bone health but carries a risk of endometrial cancer.
• The use of progestins may mitigate endometrial cancer risk, but further research is needed to assess their safety.
• Decisions regarding estrogen therapy should be individualized, based on comprehensive information about benefits and risks shared between patient and physician.
• Further research is essential to fully understand the complexities of menopause and its management.